Pharmafile Logo

Access and elimination: the future of DAAs in hepatitis C

January 25, 2017 | HCV, Pharmaphorum, hepatitis C 

Published in Pharmaphorum January 2017

The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C. 

The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.

http://www.researchpartnership.com/news/2017/01/access-and-elimination-the-future-of-daas-in-hepatit…

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Rare diseases and orphan drugs: Our experience and expertise

We have designed a complimentary infographic outlining the market opportunity as well as our experience and expertise in the growing area of rare diseases and orphan drugs, which includes links to...

Conducting research for publication video

APAC Director Pei Li Teh explains how real world insights provide an opportunity for brands to find, demonstrate and communicate their real value to patients, healthcare and society.Watch the video: https://bit.ly/2OcOWNu

Conference research case study

How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event

Portfolio analysis: Using market research to master communications across a therapeutic category

Many of us are familiar with billiard games, where two players compete to be the first to pocket all the balls on the table in a particular order.  We recently...

EphMRA round up 2018

EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.

Patients’willingness to pay

Considerations when developing an appropriate pricing strategy in self-pay markets

Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report

Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...

Scratching the surface: unmet needs in psoriasis

Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase.Psoriasis is a skin condition but its impact...

Shift to preventative healthcare – Opportunities for screening, diagnostics and vaccination

Across emerging markets we are seeing a shift towards prevention in healthcare policy, as governments seek to contain spiraling treatment costs.There is a growing, if long overdue, recognition among policy-makers...

Conference Live for ongoing congress performance measurement

Director John Branston discusses the benefits of a mobile approach for evaluating medical conferences year-on-year